Trials / Withdrawn
WithdrawnNCT00275379
Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-design, exploratory study of orally administered ERB-041 in subjects with active IC. The primary objectives of this study will be to investigate ERB-041's activity on levels of urinary APF, explore the gene expression response in peripheral blood mononuclear cells (PBMC), and to evaluate the safety of ERB-041 in women with active IC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERB-041 |
Timeline
- Start date
- 2006-08-01
- First posted
- 2006-01-11
- Last updated
- 2020-10-01
Locations
16 sites across 3 countries: United States, Austria, Germany
Source: ClinicalTrials.gov record NCT00275379. Inclusion in this directory is not an endorsement.